Is it Time to Dump Celcuity Inc (CELC) Stock After it Is Down 1.52% in a Week?

Celcuity Inc (CELC) stock is down 1.52% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Celcuity Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CELC!

See Full CELC Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CELC Stock Today?

Celcuity Inc (CELC) stock is trading at $10.34 as of 11:41 AM on Monday, Oct 23, an increase of $0.36, or 3.61% from the previous closing price of $9.98. The stock has traded between $10.14 and $10.34 so far today. Volume today is less active than usual. So far 5,471 shares have traded compared to average volume of 73,116 shares.

More About Celcuity Inc

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Click Here to get the full Stock Report for Celcuity Inc stock.